Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor
Haemophilia · 2024
DOI: 10.1111/hae.15022 ↗Kurz gefasst
Leserbrief in der Zeitschrift Haemophilia, 2024. Verfasst von Zeni Kharel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Rochester General Hospital, Rochester, USA. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Rochester General Hospital, Rochester, USA.
- Division of Hematopathology, Comprehensive Hemophilia Center and Special Coagulation Laboratory, Mayo Clinic, Rochester, Minnesota, USA.
- Mary M. Gooley Hemophilia Center, University of Rochester School of Medicine, Rochester, USA.
- Department of Hematology/Oncology, Mary M. Gooley Hemophilia Center, Rochester, New York, USA.
ORCID-Profile: Zeni Kharel, Rajiv K Pruthi
Zitieren
APA
Kharel, Z., Pruthi, R. K., Kouides, P., & Reid, R. (2024). Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor. Haemophilia. https://doi.org/10.1111/hae.15022
Vancouver
Kharel Z, Pruthi RK, Kouides P, Reid R. Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor. Haemophilia. 2024. doi:10.1111/hae.15022
BibTeX
@article{Kharel2024,
author = {Kharel, Zeni and Pruthi, Rajiv K and Kouides, Peter and Reid, Robin},
title = {Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor},
journal = {Haemophilia},
year = {2024},
doi = {10.1111/hae.15022}
}
EUVIMED